Sensitivity of BRCA1/2‐mutated tumours to platinum compounds has been validated in multiple pre‐clinical and clinical studies (Byrski et al, 2009, 2010; Silver et al, 2010; Tutt et al, 2018). Here, BRCA1 is linked to neoplasm.